Inspire Corporate Bond ETF (IBD) ETF Price Prediction 2027
Multi-horizon algorithmic price targets, Wall Street consensus calibration, reverse-DCF growth expectations & options volatility valuation
Executive Forecast Synopsis (2027)
Synthesized fundamental, multiple & technical thesis for IBD
IBD Price Forecast 2027: Our AI models project that IBD stock will rise to approximately $24.69 by 2027. This represents a potential 6.7% growth from the current trading price of $23.15. The overall market sentiment for IBD is currently neutral, based on a combination of proprietary technical signals and fundamental analysis.
About This ETF: IBD is the Inspire Corporate Bond ETF. Because an ETF tracks a basket of holdings rather than a single company, our 2027 forecast for IBD is driven primarily by price trend, momentum and volatility of the fund itself instead of company-level earnings estimates. Over the past 52 weeks the fund has traded between $22.50 and $24.78, and currently sits in the lower part of that range (29% of the way up). Investors typically use IBD to get diversified exposure to its underlying index in a single position, so the prediction above is best read as a view on the whole basket, not any individual constituent.
Technical Outlook: The stock is technically in a downtrend phase. The Relative Strength Index (RSI) is currently 49.6, which suggests the stock is trading in a neutral range. Traders should monitor key support and resistance levels closely, as a breakout or breakdown from current price consolidation will be the primary catalyst for the stock reaching the 2027 predicted target.
Quant Signal & Technical Posture
Composite equity rating reconciled with 1-year target trajectory
- TTM Squeeze ON for 20 days - volatility compression
- Price consolidating in 1.04% range for 11 days
- Moving averages converging - equilibrium state
- MACD converging near zero line - potential energy building
- Recent pattern: Hikkake pattern detected
IBD Trajectory & Forecast Curve
Projected price curve from spot ($23.15) across 30D–3Y horizons
Term Structure of Price Targets
Constant-multiple earnings trajectory model
| Horizon | Target Price | Implied Return |
|---|---|---|
| 30 Days Near-Term | $23.27 | +0.5% |
| 90 Days 1 Quarter | $23.54 | +1.7% |
| 6 Months Medium-Term | $23.92 | +3.3% |
| 1 Year Base Model | $24.69 | +6.7% |
1-Year Scenario Distribution (Bull / Base / Bear)
Probability-weighted regime outcomes around the 12-month forecast horizon
Best case scenario if strong fundamentals and market conditions align
Expected scenario based on current growth trajectory
Downside scenario if market headwinds or disappointing results
Fair Value & Core Fundamentals
PEG-adjusted intrinsic valuation & balance-sheet multiples
Technicals & Institutional Money Flow
Momentum oscillators, volume accumulation & key price levels
Volume-weighted price action shows near-term supply/distribution pressure; watch support levels for stabilization.
Institutional Research Suite for IBD
Deep-dive valuation models, options chain analytics & head-to-head peer comparisons
Frequently Asked Questions (IBD 2027 Outlook)
What is the IBD stock price prediction for 2027?
Based on our AI analysis, IBD is predicted to reach $24.69 by 2027, representing a potential 6.7% increase from the current price of $23.15.
Is IBD stock a good buy right now?
Our analysis rates IBD as a HOLD (AI Quant Score 53.0/100) based on current technical and fundamental indicators. With a projected 6.7% upside in our 1-year constant-P/E model, investors should consider their risk tolerance and investment horizon.
What is IBD 52-week high and low?
IBD has a 52-week high of $24.78 and a 52-week low of $22.50. The stock is currently trading 6.6% below its 52-week high.
What is the technical analysis for IBD?
IBD is currently in a downtrend trend. The RSI of 49.6 indicates the stock is trading in neutral territory. Traders should monitor support and resistance levels for potential entry points.
What does the IBD ETF track?
IBD is the Inspire Corporate Bond ETF. Unlike a single stock, its price reflects a basket of holdings, so our 2027 forecast is based on the fund's own price trend, momentum and volatility rather than one company's earnings.